Page last updated: 2024-12-04

2-(4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidinyl)-5-(hydroxymethyl)oxolane-3,4-diol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you described, 2-(4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidinyl)-5-(hydroxymethyl)oxolane-3,4-diol, is a **synthetic nucleoside analog**, which means it is a modified version of a naturally occurring building block of DNA and RNA.

Let's break down its structure and importance:

* **Nucleoside:** A nucleoside consists of a nitrogenous base (in this case, 4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidine) attached to a sugar molecule (here, it's a modified 5-hydroxymethyloxolane, which is similar to the ribose sugar found in RNA).
* **Modifications:** This nucleoside has several modifications that make it interesting for research:
* **4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidine:** This is a modified purine base that is not found naturally in DNA or RNA. This modification might affect its interactions with DNA or RNA polymerase enzymes, potentially leading to changes in gene expression or replication.
* **5-(hydroxymethyl)oxolane:** This modified sugar molecule might also impact how the nucleoside interacts with other components of cellular machinery.

**Why is it important for research?**

Nucleoside analogs are valuable tools for research because they can:

* **Inhibit DNA and RNA synthesis:** Many nucleoside analogs act as antiviral or anticancer agents by blocking the replication of viruses or the growth of cancer cells.
* **Probe cellular processes:** By incorporating these analogs into DNA or RNA, researchers can study the function of different cellular pathways and processes.
* **Develop new therapeutics:** Researchers continuously investigate new nucleoside analogs with improved efficacy and safety profiles for treating various diseases.

**Specific Potential Applications:**

Given its structure, the compound you mentioned could be investigated for its potential to:

* **Inhibit viral replication:** The modified purine base and sugar could interfere with the replication of viruses, making it a potential antiviral agent.
* **Target specific enzymes:** The compound might selectively inhibit certain enzymes involved in DNA or RNA synthesis, which could be useful for treating specific diseases.
* **Modify gene expression:** The modified nucleoside could potentially be incorporated into DNA or RNA, leading to changes in gene expression or protein production.

**Note:** The exact properties and potential applications of this specific nucleoside analog would need to be studied further in laboratory experiments.

Cross-References

ID SourceID
PubMed CID1830
CHEMBL ID63388
CHEBI ID93817
SCHEMBL ID2043545

Synonyms (41)

Synonym
BRD-A18497530-001-03-8
BRD-A18497530-001-04-6
BIO2_000444
BIO2_000924
BSPBIO_001227
BIOMOLKI2_000055
IDI1_002199
nsc113939
nsc-113939
BIOMOLKI_000049
NCGC00163302-01
NCGC00163302-03
NCGC00163302-02
NCGC00096117-01
4-amino-5-iodo-7-(beta-d-ribofuranosyl)pyrrolo[2,3-d]pyrimidine
KBIO3_001014
KBIO2_005703
KBIO2_000567
KBIOGR_000567
KBIOSS_000567
KBIO3_001013
KBIO2_003135
NCGC00163302-04
HMS1990M09
BMK1-F1
HMS1792M09
HMS1362M09
CHEMBL63388
CCG-100653
FT-0620520
4-amino-5-iodo-7-(b-d-ribofuranosyl)pyrrolo[2,3-d]pyrimidine;7-iodotubercidin
SCHEMBL2043545
7-deaza-7-iodoadenosine
WHSIXKUPQCKWBY-UHFFFAOYSA-N
CHEBI:93817
AKOS030242162
Q27165541
2-(4-amino-5-iodo-7-pyrrolo[2,3-d]pyrimidinyl)-5-(hydroxymethyl)oxolane-3,4-diol
444020-71-7
Z2216889315
7-iodo-7-deaza-d-guanosine

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nucleobase-containing molecular entityAny compound that has a nucleobase as a part.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency2.32250.004110.890331.5287AID624247; AID624248; AID624249; AID624251; AID686934
TDP1 proteinHomo sapiens (human)Potency0.54090.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency26.79050.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency9.46620.531815.435837.6858AID504845
67.9K proteinVaccinia virusPotency22.14000.00018.4406100.0000AID720579; AID720580
dual specificity tyrosine-phosphorylation-regulated kinase 1A isoform 1Homo sapiens (human)Potency0.01300.01307.487829.1922AID624093
mitogen-activated protein kinase 1Homo sapiens (human)Potency3.16230.039816.784239.8107AID995
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency4.80230.00798.23321,122.0200AID2546; AID2551
survival motor neuron protein isoform dHomo sapiens (human)Potency4.03210.125912.234435.4813AID1458
dual specificity protein kinase CLK4Homo sapiens (human)Potency0.01160.01163.786731.6228AID624094
lamin isoform A-delta10Homo sapiens (human)Potency2.81840.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.20 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]